China OKs 2 more virus vaccines for wider use
Thursday, February 25, 2021
|
TAIPEI, Taiwan (AP) — China has approved two more COVID-19 vaccines for wider use, adding to its growing arsenal of shots.
It gave conditional approval to a vaccine from CanSino Biologics and one from state-owned Sinopharm. Both are already used among select groups of people under an emergency use authorization. China now has four vaccines to immunize its population of 1.3 billion people.
CanSino's COVID-19 vaccine is the first developed by a Chinese company that requires only one shot. Both vaccines can be stored between two and eight degrees Celsius.
CanSino says its vaccine candidate is 65.28 per cent effective 28 days after the dose is given. A Sinopharm subsidiary, the Wuhan Institute of Biologics, says its vaccine candidate is 72.51 per cent effective.
Neither company has publicly released final testing data showing safety and efficacy.
Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at https://bit.ly/epaper-login
ADVERTISEMENT
POST A COMMENT
HOUSE RULES
- We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper; email addresses will not be published.
- Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.
- We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.
- Please do not write in block capitals since this makes your comment hard to read.
- Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.
- If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.
- Lastly, read our Terms and Conditions and Privacy Policy